Loading...
Clinical development of anti‐CD19 chimeric antigen receptor T‐cell therapy for B‐cell non‐Hodgkin lymphoma
B‐cell non‐Hodgkin lymphoma (B‐NHL) is the most frequent hematological malignancy. Although refined chemotherapy regimens and several new therapeutics including rituximab, a chimeric anti‐CD20 monoclonal antibody, have improved its prognosis in recent decades, there are still a substantial number of...
Na minha lista:
| Udgivet i: | Cancer Sci |
|---|---|
| Main Authors: | , , |
| Format: | Artigo |
| Sprog: | Inglês |
| Udgivet: |
John Wiley and Sons Inc.
2017
|
| Fag: | |
| Online adgang: | https://ncbi.nlm.nih.gov/pmc/articles/PMC5480083/ https://ncbi.nlm.nih.gov/pubmed/28301076 https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1111/cas.13239 |
| Tags: |
Tilføj Tag
Ingen Tags, Vær først til at tagge denne postø!
|